JHVEPhoto/iStock Editorial via Getty Images
Teva Pharmaceuticals Industries (NYSE:TEVA) is expected to report higher Q3 earnings early Wednesday, with investors watching to see if the company revises its outlook as it did last quarter.
Analysts, on average, estimate the Israeli drugmaker will post adjusted EPS of $0.61 on revenue of $3.74B. For Q3 2022, the company missed estimates for both the top and bottom lines, reporting adjusted EPS of $0.59 on revenue of $3.6B.
Last quarter, Teva beat the Street on both adjusted EPS and revenue. Over the last two years, Teva has topped consensus estimates six times for adjusted EPS and five times for revenue.
Teva watchers will also be looking to see if the company updates its forecast. Last quarter, Teva raised its 2023 revenue outlook to $15B to $15.4B.
Analysts, on average, now see 2023 revenue climbing 1.6% year-over-year to $15.17B.